INDAPAMIDE Drug Patent Profile

When do Indapamide patents expire, and what generic alternatives are available?

Indapamide is a drug marketed by Actavis Elizabeth, Ani Pharms, Aurobindo Pharma Usa, Chartwell Rx, Rising, Teva, and Watson Labs. and is included in nine NDAs.

The generic ingredient in INDAPAMIDE is indapamide. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the indapamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Indapamide

A generic version of INDAPAMIDE was approved as indapamide by ANI PHARMS on July 27^th, 1995.

Summary for INDAPAMIDE

US Patents:	0
Applicants:	7
NDAs:	9

US Patents and Regulatory Information for INDAPAMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	INDAPAMIDE	indapamide	TABLET;ORAL	074722-001	Jun 17, 1996	AB	RX	No	No
Watson Labs	INDAPAMIDE	indapamide	TABLET;ORAL	074585-002	Sep 26, 1996		DISCN	No	No
Ani Pharms	INDAPAMIDE	indapamide	TABLET;ORAL	074498-001	Oct 31, 1996		DISCN	No	No

Last updated: July 5, 2026

Indapamide Investment Scenario and Fundamentals Analysis: Patent, Exclusivity, Market Dynamics, and Generic Entry Risk

Indapamide is a long-established, off-patent oral diuretic used for hypertension and edema-associated conditions. Investment upside is typically driven by (1) portfolio positioning in generics and authorized brands in specific markets, (2) product-formulation differentiation where still protected, and (3) contract-manufacturing and regulatory execution rather than novel R&D timelines. In the U.S., Indapamide is generally treated as a generic opportunity with limited practical patent overhang for new entrants.

What’s the core investment thesis for indapamide?

• Product type: Small-molecule, oral diuretic.
• Typical business model: Generic manufacturing, authorized generics, and line extensions via immediate-release (IR) and extended-release (ER).
• Primary value driver: Regulatory readiness (ANDA filings, bioequivalence, product quality) and cost-efficient production.
• Main downside: Price compression, intense generic competition, and fast-margin decay after approvals.

---

Is indapamide a good investment for a generic portfolio: market size, pricing pressure, and revenue exposure

Indapamide is not a “blockbuster” branded product globally; it is widely available as generic therapy. Investment cases usually hinge on localized demand stability, formulary placement, and ability to defend against margin collapse.

Revenue dynamics investors should model

• Price compression risk: Generic diuretics are frequently price-led at launch and then erode after multiple approvals.
• Share capture mechanics: Access and substitution rules, pharmacy benefit contracts, and wholesaler stocking determine real revenue capture.
• Unit demand durability: Hypertension prevalence drives baseline demand, but adherence and switching are influenced by payer incentives and competing generics (thiazides, chlorthalidone, hydrochlorothiazide, loop diuretics, ARB/ACE inhibitor combos).

Where indapamide can still produce acceptable returns

• Product differentiation pockets: ER vs IR, differing release kinetics, and excipient-driven tolerability profiles can matter in physician prescribing and patient adherence.
• Geographic density: Opportunities exist where regulatory delays or supply constraints reduce competition speed (timing matters more than novelty).
• Manufacturing scale: Contract manufacturing economics and strong QC reduce COGS volatility and batch rejection risk.

---

What patents protect indapamide in 2026 and how strong is the patent estate

Indapamide’s original development dates to the late 1960s/1970s. For investment decisioning, the key point is that active, enforceable primary compound coverage is typically expired in major markets.

What usually remains after compound patent expiry

• Formulation patents (ER mechanisms, matrix systems, coatings, release-control)
• Process patents (API purification crystallization, impurity control)
• Method-of-use patents (less common for a mature, guideline-recommended diuretic)

Practical investment takeaway

For a new generic entrant, most of the value depends on:

• whether any meaningful formulation/process patents remain in a target geography for the specific dosage form (ER vs IR), and
• whether those patents are asserted or litigated, which affects launch timing and settlement probability.

---

When does indapamide lose exclusivity in key jurisdictions (U.S., EU, UK)

United States (FDA/Orange Book-driven exclusivity)

Indapamide products are generally mature and widely marketed. Investment modeling should assume no meaningful U.S. regulatory exclusivity barrier for basic generics beyond what is listed in FDA’s Orange Book for specific NDA/ANDA references.

European Union (marketing authorization and data exclusivity)

In the EU, exclusivity in older small-molecule products largely flows from first authorization, later line extensions, or specific data protections. Indapamide’s original authorization history typically places it outside meaningful regulatory exclusivity for brand-level exclusivity today.

UK (post-Brexit regulatory alignment)

UK authorizations typically mirror EU pathways historically used, with exclusivity largely expired for mature generics.

---

What is the Orange Book status of indapamide and which listings matter for Paragraph IV risk

For U.S. Paragraph IV strategy, the decision depends on which Orange Book listings exist for the specific strength/dosage form (IR vs ER) and whether there are listed patents tied to that drug product.

Paragraph IV relevance for indapamide

• If only expired patents are listed: Paragraph IV is not a strategic pathway because launch timing is not blocked by active patents.
• If formulation/process patents are still listed: Paragraph IV can become relevant, but the investment thesis should incorporate litigation and potential settlement.

Dosage-form specificity matters

Indapamide can be marketed as:

• Immediate-release (IR) tablets
• Extended-release (ER) tablets

Patent coverage and Orange Book listings usually differ by dosage form, so risk assessment must be dosage-form specific.

---

How many ANDAs for indapamide exist and what does that imply for future generic launch timing

A mature generic market often has:

• multiple ANDA holders,
• rapid substitution after approval,
• and low differentiation in pricing.

Investment implication

• Market saturation usually means new approvals do not create pricing power.
• Launch timing becomes the only lever: the earlier you file and clear regulatory hurdles, the more you can ride the temporary price headroom.

---

What generic entry risks exist for indapamide (litigation, settlements, and regulatory bottlenecks)

Patent litigation risk profile

For older molecules like indapamide, litigation risk is typically not “compound-driven” but rather tied to:

• late-life formulation patents,
• patent-listed ER characteristics,
• or specific manufacturing processes.

Settlement risk profile

If any active patents exist for the exact referenced drug product, settlement can:

• delay entry,
• impose authorized generic arrangements,
• or require design-around changes.

Regulatory and CMC bottlenecks that actually matter

• batch consistency for ER release characteristics,
• impurity control and residual solvents,
• dissolution profile matching and stability data,
• and ability to pass inspections without remediation costs.

---

How does indapamide compare with competing diuretics and what does that mean for formularies

Indapamide competes with:

• hydrochlorothiazide (HCTZ)
• chlorthalidone
• loop diuretics (furosemide, bumetanide) in selected populations
• combo therapies (often ARB/ACE inhibitor plus diuretic)

Key competitive factors

• Dose and tolerability perception
• clinical guideline positioning
• payer preference for “first-line” low-cost diuretics
• patient-specific response and electrolyte monitoring patterns

Investment implication

Indapamide’s strongest role is as a low-cost, guideline-compatible diuretic. That supports demand but limits margin expansion.

---

What formulations are protected for indapamide (ER vs IR) and how do they affect design-around strategies

Formulation patent themes to search for in mature diuretics

• ER matrix compositions (hydrophilic/hydrophobic polymer systems)
• coating systems controlling dissolution
• excipient selection affecting release kinetics
• manufacturing parameters that influence particle size distribution and dissolution

Investment effect

• If ER is patented, generic entrants may need a design-around that preserves dissolution profile and stability while avoiding claim scope.
• If IR has fewer active protections, IR launches may be faster than ER.

---

What manufacturing/IP barriers exist for indapamide API and tablets

Even in off-patent space, barriers persist:

• API impurity specifications that are hard to meet consistently
• crystal form and polymorph control in some API production routes
• ER dissolution targets that require process tuning

Investment implication

For a sponsor, the “IP barrier” can be less about patents and more about process capability and inspection outcomes. That shifts investment from legal to operational readiness.

---

What FDA regulatory pathway applies to indapamide generics and what milestones drive approval

Indapamide generic approvals typically follow:

• ANDA (bioequivalence to a reference listed drug)

Key milestone drivers for investor forecasting

• BE protocol design and execution timelines
• dissolution testing alignment and formulation bridge packages
• CMC completeness for drug product and API
• inspection schedules and response times

---

Which companies sell indapamide and how does competitive intensity affect margins

Competitive intensity is generally high in mature diuretics due to:

• multiple ANDA entrants,
• pharmacy substitution behavior,
• and aggressive wholesaler contracting.

Investment implication

A new entrant’s margin durability depends on:

• contract terms and distribution agreements,
• ability to secure formulary presence,
• and supply reliability.

---

What patent litigation affects indapamide and what settlement patterns appear in mature diuretic markets

For mature generics:

• litigation is usually narrow and dosage-form specific,
• settlements often include “no-early-launch” provisions,
• and authorized generic arrangements can be used to protect near-term revenue.

How to model legal overhang in indapamide

• treat legal risk as a timing variable rather than a long exclusivity moat,
• and build base-case scenarios assuming at most a short delay unless an active formulation patent is clearly asserted.

---

Investment scenario framework: how to value indapamide opportunities vs. other off-patent diuretic bets

Scenario model (high-level)

Base case (most likely for off-patent diuretics):

• approvals proceed without meaningful patent delay,
• price settles quickly,
• revenue scales with volume not margin.

Bull case:

• limited ER competition in a given geography/strength,
• faster regulatory clearance due to strong CMC,
• short-term supply constraints allow temporary pricing.

Bear case:

• litigation over dosage-form specifics delays entry,
• payer contracting reduces realized price,
• inspection or BE/dissolution issues create resubmission cycles.

---

Key decision checklist for investors evaluating indapamide

1. Dosage-form target: ER vs IR affects patent landscape and approval complexity.
2. Geography: regulatory and listed patent status vary by country.
3. Orange Book/EMA patent lists: confirm whether any enforceable listings map to the specific strength/reference product.
4. CMC capability: ensure ER dissolution and impurity control are production-ready.
5. Launch strategy: prioritize markets with slower competition ramp and strong distributor leverage.
6. Cost curve discipline: assume margin compression; optimize COGS and batch success rate.

---

Key Takeaways

• Indapamide is a mature, off-patent diuretic where investment returns typically come from execution and scale, not long-duration exclusivity.
• The main practical risks are quick price erosion, dose-form-specific patent or formulation issues, and CMC/regulatory execution.
• For investors, the highest-signal work is dosage-form and geography-specific clearance plus a production-capability plan that minimizes resubmission and inspection remediation risk.

---

FAQs

1) Is indapamide IR or ER more attractive for a generic launch from a risk standpoint?

ER can carry higher formulation and CMC complexity due to release kinetics, while IR can be faster. The risk profile depends on active formulation listings for the referenced drug product in the target geography.

2) What is the most important regulatory package for indapamide ANDAs besides BE?

Drug product dissolution testing alignment and a complete CMC dossier for both drug product and API impurity controls are usually the gating items.

3) Can indapamide be used as a portfolio hedge in off-patent hypertension markets?

Yes. Hypertension demand tends to be stable, and diuretics often have broad payer acceptance, though pricing cycles can be aggressive.

4) Do formulation design-arounds matter more than process patents for indapamide generics?

Often design-arounds around ER dissolution and excipient/matrix systems matter more for claim scope than generic process differences, but it depends on what patents are listed and asserted.

5) What is the fastest route to commercialization for indapamide in competitive markets?

A route anchored in strong CMC readiness and rapid regulatory filing strategy, timed to avoid active patent obstacles tied to the exact dosage form/strength.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. ANDA Bioequivalence Studies Guidance for Industry. U.S. Food and Drug Administration. https://www.fda.gov/